ImmunityBio
Stock Forecast, Prediction & Price Target
ImmunityBio Financial Estimates
ImmunityBio Revenue Estimates
ImmunityBio EBITDA Estimates
ImmunityBio Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $934K N/A | $240K -74.30% | $622K 159.16% | Avg: $277.38M Low: $246.56M High: $308.19M avg. 44495.65% | Avg: $521.22M Low: $421.05M High: $621.39M avg. 87.90% | Avg: $794.70M Low: $641.97M High: $947.42M avg. 52.46% | Avg: $1.07B Low: $864.82M High: $1.27B avg. 34.71% |
Net Income
% change YoY
| $-349.84M N/A | $-417.32M -19.28% | $-583.19M -39.74% | Avg: $-306.50M Low: $-300.09M High: $-213.62M avg. 47.44% | Avg: $-80.27M Low: $11.44M High: $19.07M avg. 73.81% | Avg: $157.67M Low: $118.28M High: $197.07M avg. 296.42% | Avg: $289.92M Low: $217.48M High: $362.35M avg. 83.87% |
EBITDA
% change YoY
| $-316.30M N/A | $-343.97M -8.74% | $-436.18M -26.80% | Avg: $-277.38M Low: $-308.19M High: $-246.56M avg. 36.40% | Avg: $-521.22M Low: $-621.39M High: $-421.05M avg. -87.90% | Avg: $-794.70M Low: $-947.42M High: $-641.97M avg. -52.46% | Avg: $-1.07B Low: $-1.27B High: $-864.82M avg. -34.71% |
EPS
% change YoY
| -$0.9 N/A | -$1.04 -15.55% | -$1.15 -10.57% | Avg: -$0.51 Low: -$0.59 High: -$0.42 avg. 56.08% | Avg: $0.03 Low: $0.02 High: $0.04 avg. 105.94% | Avg: $0.31 Low: $0.23 High: $0.39 avg. 933.33% | Avg: $0.57 Low: $0.43 High: $0.71 avg. 83.87% |
Operating Expenses
% change YoY
| $331.21M N/A | $350.85M 5.93% | $362.87M 3.42% | Avg: $51.04B Low: $45.37B High: $56.71B avg. 13967.29% | Avg: $95.91B Low: $77.48B High: $114.35B avg. 87.90% | Avg: $146.24B Low: $118.14B High: $174.35B avg. 52.46% | Avg: $197.01B Low: $159.15B High: $234.87B avg. 34.71% |
FAQ
What is ImmunityBio stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 125.38% in 2025-2028.
We have gathered data from 2 analysts. Their low estimate is -300.09M, average is -306.50M and high is -213.62M.
What is ImmunityBio stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 11167.68% in 2025-2028.
We have gathered data from 2 analysts. Their low revenue estimate is $246.56M, average is $277.38M and high is $308.19M.
What is ImmunityBio stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 294.80% in 2025-2028.
We have gathered data from 2 analysts. Their low earnings per share estimate is -$0.59, average is -$0.51 and high is $-0.42.
What is the best performing analyst?
In the last twelve months analysts have been covering ImmunityBio stock. The most successful analyst is Kelly Shi whose win rate is 100%. He has correctly predicted 1/1 price targets.